Swiss Nuclide AG is working towards making precision diagnostics and therapy accessible worldwide by developing new diagnostic and therapeutic PET tracers. Their goal is to create a portfolio of optimized tracers for targeted cancer treatment and diagnosis. They use copper-based radiopharmaceuticals to achieve high accuracy and accessibility, and their innovative "diagnostic to therapeutic" approach reduces development risks. Swiss Nuclide AG aims to bring flexibility and improved safety and efficacy to medical facilities in the field of precision radio-oncology.